Feb 23, 2022 08:08 PM

In Depth: Could Pfizer’s Drug Paxlovid Change China’s Covid Policy?

China’s approval for the import of Pfizer’s new Covid-19 drug surprised many.

The National Medical Products Administration’s (NMPA) conditional approval for the Paxlovid came with unprecedented haste, especially given how bearish the country has been on foreign-made Covid-19 treatments. The green light came on Feb. 12, barely two months after the U.S. Food and Drug Administration signed off on it.

You've accessed an article available only to subscribers
Share this article
Open WeChat and scan the QR code
Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription